Sponsored by Cara Therapeutics
This activity is not certified for credit.
Friday, September 8
Clinicians who care for patients with chronic pain are being urged to consider alternatives to traditional mu opioid analgesics due to the public health epidemics of abuse, addiction, and overdose. Unfortunately, there are relatively limited pharmacologic classes of analgesics currently available, and these agents provide analgesia to varying degrees, but also have a range of side effects that limit their use. In this environment, the National Pain Strategy has called for research to enhance drug discovery for safer opioids and non-opioid analgesics.
A novel peripherally acting kappa opioid receptor agonist, CR845, is currently in Phase 3 trials for post-operative pain (IV CR845) and in Phase 2 trials for chronic pain (oral CR845). Because of its unique pharmacologic properties, CR845 has been shown to produce significant analgesia with low abuse potential and little-to-no traditional centrally acting mu opioid side effects, such as nausea and vomiting, pruritus, and respiratory depression.
Please join us for this PDM program, where the faculty will identify the clinical need for analgesics with novel mechanisms of action, describe the pharmacology of CR845, and present clinical trial data for CR845 in the treatment of acute and chronic pain.
After attending this PDM program, participants should be better able to:
Michael J. Brennan, MD
Joseph W. Stauffer, DO, MBA
Posted on August 16, 2017